Reduction of cardiotoxicity of an antitumor agent using...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/675 (2006.01) A61K 31/198 (2006.01) A61K 31/28 (2006.01) A61K 31/335 (2006.01) A61K 31/44 (2006.01) A61K 31/4415 (2006.01) A61K 31/444 (2006.01) A61K 31/70 (2006.01) A61K 33/32 (2006.01)

Patent

CA 2259150

The invention relates to the use of certain chelating agents and their metal chelates and to the use of certain manganese containing compounds, in particular manganese chelates, in the manufacture of a therapeutic agent for use in reducing the cardiotoxicity of an antitumor agent. Such compounds are particularly effective in reducing the side-effects of anthracycline drugs and/or paclitaxel.

L'invention concerne l'utilisation de certains agents chélatants et de leurs chélates de métaux, ainsi que de certains composés contenant du manganèse, en particulier des chélates de manganèse, dans la préparation d'un agent thérapeutique servant à diminuer la cardiotoxicité d'un agent anti-tumeurs. Ces composés sont particulièrement efficaces pour diminuer les effets secondaires de médicaments à base d'anthracycline et/ou du paclitaxel.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Reduction of cardiotoxicity of an antitumor agent using... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reduction of cardiotoxicity of an antitumor agent using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of cardiotoxicity of an antitumor agent using... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1938164

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.